PF-Atlas › Clinical Trials › NCT07454291
A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 in Healthy Participants
taladegib · Phase 1
Registry ID
NCT07454291
Phase
Phase 1
Status
Recruiting
Drug / intervention
taladegib
Sponsor
Endeavor Biomedicines, Inc.
Start
2026-04-28
Enrollment
57
Locations
2
About this trial
The purposes of this study are to: 1. evaluate potential interactions between taladegib (ENV-101) and current standard-of-care (SOC) therapies for idiopathic pulmonary fibrosis (IPF), including nintedanib and pirfenidone, and 2. more fully characterize the pharmacokinetics (PK) of taladegib (i.e., how the body absorbs, distributes, metabolizes and excretes taladegib). This study will enroll 4 cohorts (groups) of participants. Each cohort will experience a different duration of treatment and sequestering (being housed) at the clinical site, followed by a 14-day follow-up period for safety evaluation. The longest duration of treatment for any cohort is 30 days.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT07454291 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.